CoChat
Sign Up
Cited by 107Treatment of Major DepressionMultiple Sclerosis Research StudiesAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.

Efficacy of paroxetine in treating major depressive disorder in persons with multiple sclerosis

Ehde, Dawn M., Kraft, George H., Chwastiak, Lydia, Sullivan, Mark D., Gibbons, Laura E., Bombardier, Charles H., Wadhwani, Rohini·2008·General Hospital Psychiatry
DOI 10.1016/j.genhosppsych.2007.08.002
Open this paper in CoChat — free account

Abstract

Objective The objective of this study was to evaluate the efficacy of paroxetine in treating major depressive disorder (MDD) in persons with multiple sclerosis (MS).Method In this double-blind trial, 42 participants with MS and MDD were randomly assigned to one of two parallel 12-week treatment arms: paroxetine or placebo. The participants started at an initial dose of 10 mg/day paroxetine or placebo, titrated up to 40 mg daily based on symptoms response and side effects. The primary outcome measure was the Hamilton Rating Scale for Depression (HAM-D). Secondary outcomes included fatigue, anxiety and self-reported quality of life.Results Intent-to-treat analyses revealed that both groups improved from pretreatment to posttreatment. Although the treatment group improved more than the control group on most measures, few differences were statistically significant. For the primary outcome, 57.1% of participants in the treatment arm had at least a 50% reduction in HAM-D score, compared with 40% in the control group (nonsignificant). Treatment effects were greater among the participants who completed the study; 78.6% of completers had a treatment response compared with 42.1% of controls (P=.073).Conclusion Although paroxetine may not be efficacious for all persons with MS and MDD, it appears to benefit some individuals.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.genhosppsych.2007.08.002

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 47 references

Research works printed but not linked: 1

  1. American Psychiatric Association, 2000, Practice guidelines for the treatment of patients with major depressive disorder, Am J Psychiatry Supplement, 157, 1

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Ehde, D. M., Kraft, G. H., Chwastiak, L., Sullivan, M. D., Gibbons, L. E., Bombardier, C. H., & Wadhwani, R.
Affiliations
  • University of Washington (US)
  • Yale University (US)
Corresponding author
Ehde, Dawn M.
ORCID
Venue
General Hospital Psychiatry
Publisher
Elsevier BV
Published
2008-01
Volume
30
Issue
1
Pages
40-48
ISSN
0163-8343 (ISSN-L)
DOI
10.1016/j.genhosppsych.2007.08.002
OpenAlex
W2086423905
Cited by
107
References
47
Citations by year
2026: 1 · 2025: 3 · 2024: 3 · 2023: 7 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 4 · 2018: 3 · 2017: 11 · 2016: 7 · 2015: 10 · 2014: 9 · 2013: 7 · 2012: 11
FWCI
5.14
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • General Hospital Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • GlaxoSmithKline
  • National Institute on Disability and Rehabilitation Research
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords
paroxetine, major depressive disorder, multiple sclerosis, antidepressant efficacy, selective serotonin reuptake inhibitors, fatigue, anxiety, quality of life, treatment response
MeSH terms
Adult, Major Depressive Disorder, Double-Blind Method, Female, Humans, Male, Middle Aged, Multiple Sclerosis, United States, Washington, Comorbidity, Treatment Outcome, Outcome Assessment, Health Care, Paroxetine, Antidepressive Agents, Second-Generation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review